Shenzhen Hybio Engineering Co., Ltd. (HYBIO) reached an agreement with SAIF and Shenzhen Venture Capital Co., Ltd. (SZVC). It received US$15M financing in the initial round from the said two VC firms, thus achieving win-win. 

The investors look well of the prospects of HYBIO and the industry it lies in - bio/healthcare industry. Currently, diverse peptide industry has become one of the fastest growing segments in bio/healthcare industry. Researches show with development edge, the global diverse peptide industry is going to grow over 15% annually within five years.   

Shenzhen-based leading enterprises in biomedicine and medical instruments have become favorite targets for VC community and capital market. Over the years, HYBIO has become the leading figure and the largest-scale R&D centre of peptide industry in China. It boasts huge market vision and investment value.